Global Primary Biliary Cholangitis Market – Industry Trends and Forecast to 2029

Análisis y tamaño del mercado

La cirrosis biliar primaria es una enfermedad hepática crónica que produce inflamación, fibrosis y obstrucción de los conductos biliares, lo que provoca la pérdida de pequeños conductos biliares dentro del hígado. La autoinmunidad, la infección y/o la predisposición genética son todas posibles causas de la cirrosis biliar primaria. El prurito, la osteoporosis, el colesterol alto en sangre y la mala absorción de grasas y vitaminas liposolubles son síntomas de la cirrosis biliar primaria, que puede progresar a hepatomegalia e hiperpigmentación, esplenomegalia, ictericia, síndrome seco o anillos de Kayser-Fleischer. La cirrosis biliar primaria se desarrolla con el tiempo y puede acabar provocando que el hígado deje de funcionar por completo.

Data Bridge Market Research analiza que el mercado de colangitis biliar primaria se valoró en USD 784,81 millones en 2021 y se espera que alcance los USD 1.744,47 millones para 2029, registrando una CAGR del 10,50% durante el período de pronóstico de 2022 a 2029. Además de los conocimientos del mercado, como el valor de mercado, la tasa de crecimiento, los segmentos del mercado, la cobertura geográfica, los actores del mercado y el escenario del mercado, el informe de mercado curado por el equipo de Data Bridge Market Research también incluye un análisis de expertos en profundidad, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Alcance del informe y segmentación del mercado

Definición de mercado

La colangitis biliar primaria, también conocida como cirrosis biliar primaria, es una enfermedad hepática crónica en la que los conductos biliares se dañan gradualmente. No se conoce ningún tratamiento para la colangitis biliar primaria. Para controlar los síntomas y reducir la progresión de la colangitis biliar primaria, los médicos recetan medicamentos. El ursodiol ayuda a eliminar la bilis del hígado. En muchos casos, este medicamento mejora la función hepática y retrasa la evolución de la enfermedad hepática. Si el ácido ursodesoxicólico (UDCA) no es eficaz o no se tolera, se utiliza ácido obeticólico solo o en combinación con él. Este tratamiento reduce la producción de bilis al tiempo que aumenta el flujo biliar fuera del hígado. Existen otras opciones farmacológicas según las circunstancias individuales de cada paciente y la existencia de otros trastornos médicos. Si la función hepática continúa deteriorándose después del tratamiento médico, puede ser necesario un trasplante de hígado.

Dinámica del mercado de la colangitis biliar primaria

Conductores

• Aumento de la prevalencia de colangitis biliar primaria

Se estima que la creciente prevalencia de la colangitis biliar primaria en todo el mundo mejorará el crecimiento del mercado. La colangitis biliar primaria (CBP) es una enfermedad poco común que causa un trastorno hepático persistente y progresivo. Afecta principalmente a las mujeres y suele aparecer entre los 30 y los 60 años. La CBP suele afectar al pequeño conducto biliar del hígado. La colangitis biliar primaria se divide en cuatro fases: etapa 1 (sin cicatrices) a etapa 4 (cirrosis). Una combinación de causas, incluidos factores autoinmunes, genéticos y ambientales, pueden causar CBP.

• Aumentar la inversión en infraestructura sanitaria

Otro factor importante que influye en la tasa de crecimiento del mercado de la colangitis biliar primaria es el aumento del gasto sanitario, que ayuda a mejorar su infraestructura. Además, varias organizaciones gubernamentales tienen como objetivo mejorar la infraestructura sanitaria aumentando la financiación, lo que influirá aún más en la dinámica del mercado.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the primary biliary cholangitis market. Additionally, the sedentary lifestyle of people such as high alcohol consumption and addiction of smoking will result in the expansion of primary biliary cholangitis market. Rising level of disposable income and surging geriatric population are the major factors anticipated to flourish the market’s growth rate during the forecast period of 2022-2029.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the primary biliary cholangitis market growth. The primary biliary cholangitis treatment market is anticipated to grow because to an increase in pipeline research to discover prominent medicines for rare diseases such as primary biliary cholangitis. For instance, CymaBay Therapeutics, Inc. started a placebo-controlled, randomised phase 3 clinical trial for seladelpar 5-10mg in October 2018. The researchers wanted to see if seladelpar was safe and effective in individuals with primary biliary cholangitis (PBC) and if there was an inadequate response or intolerance to ursodeoxycholic acid (UDCA). The research was expected to be finished in December 2021. 

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the primary biliary cholangitis market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the treatment will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the primary biliary cholangitis market. Additionally, strict regulatory policies and lack of awareness among people will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This primary biliary cholangitis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the primary biliary cholangitis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Primary biliary cholangitis market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Recent Development

• In May 2022, Intercept Pharmaceuticals, Inc. announced that the first patient has been dosed in a Phase 2 study evaluating a fixed-dose combination of obeticholic acid (OCA) and bezafibrate (BZF) for treating patients suffering from primary biliary cholangitis (PBC) who have not achieved an adequate biochemical response to ursodeoxycholic acid.

Global Primary Biliary Cholangitis Market Scope

The primary biliary cholangitis market is segmented on the basis of treatment type, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment Type

• Liver Transplantation
• Drug Therapy
• Ursodeoxycholic acid (UDCA)
• Obeticholic acid
• Fibrates
• Budesonide
• Others

Diagnosis

• Imaging Tests
• Magnetic resonance elastography (MRE)
• Magnetic resonance cholangiopancreatography (MRCP)
• Ultrasound
• FibroScan
• Blood Tests
• Cholesterol test
• Antibody tests
• Liver tests
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Primary Biliary Cholangitis Market Regional Analysis/Insights

The primary biliary cholangitis market is analyzed and market size insights and trends are provided by country, treatment type, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the primary biliary cholangitis market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the primary biliary cholangitis market because of the rising prevalence of primary biliary cholangitis and technological advancement in the treatment in this region. Additionally, rising healthcare expenditure and the presence of major key players will further propel the market’s growth rate.

Asia-Pacific are expected to grow during the forecast period of 2022-2029 due to increasing number of geriatric population and surging level of disposable income in this region. Also, development of healthcare infrastructure and rising government initiatives will further propel the market’s growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Primary Biliary Cholangitis Market Share Analysis

The primary biliary cholangitis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to primary biliary cholangitis market.

Some of the major players operating in the primary biliary cholangitis market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Ireland)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Novartis AG (Switzerland)
• Merck & Co., Inc. (U.S.)
• Allergan (Ireland)
• AstraZeneca (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Hikma Pharmaceuticals PLC (U.K.)
• Bristol-Myers Squibb Company (U.S.)
• Bayer AG (Germany)
• Boehringer Ingelheim International GmbH. (Germany)
• Dr. Reddy’s Laboratories Ltd. (India)
• Gilead Sciences, Inc. (U.S.)
• Amgen Inc. (U.S.)
• Eli Lilly and Company (U.S.)
• AbbVie Inc. (U.S.)
• Lupin (India)
• Allergan (Ireland)

SKU-53498